Millendo Therapeutics, Inc. (MLND)
Stock Price:
$1.83 USD
0.02 (1.10%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
34.77M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-47.00M |
| Shares Out |
19.00M |
| EPS (ttm) |
-2.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$1.83 |
| Previous Close |
$1.81 |
| Change ($) |
0.02 |
| Change (%) |
1.10% |
| Day's Open |
1.81 |
| Day's Range |
1.78 - 1.88 |
| Day's Volume |
201,830 |
| 52-Week Range |
1.26 - 9.88 |
More Stats
| Market Cap |
34.77M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.00M |
| Float |
15.43M |
| EPS (basic) |
-2.95 |
| EPS (diluted) |
-2.87 |
| FCF / Share |
-2.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
686,349 |
| Short Ratio |
2.56 |
| Short % of Float |
4.45% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.78 |
| Revenue |
n/a |
| Operating Income |
-47.51M |
| Net Income |
-47.00M |
| Free Cash Flow |
-38.22M |
| Net Cash |
47.54M |
| Net Cash / Share |
2.50 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-47.15% |
| ROE |
-94.03% |
| ROIC |
-1,902.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.33*
(136.61% upside)
Low
3.00
Current: $1.83
High
5.00
Target: 4.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | 0.65 | 0.28 | - | - | - |
| Revenue Growth | - | - | - | 135.74% | - | - | - | - |
| Gross Profit | - | - | - | -4.75 | -1.97 | - | - | - |
| Operating Income | -45.61 | -27.04 | -84.33 | -81.01 | -72.00 | -47.93 | -29.13 | -13.53 |
| Net Income | -44.57 | -27.19 | -84.58 | -82.26 | -73.22 | -49.52 | -29.04 | -13.51 |
| Shares Outstanding | 13.71 | 1.55 | 0.26 | 2.14 | 1.81 | 1.51 | 1.08 | 0.39 |
| Earnings Per Share | -3.25 | -17.58 | -321.81 | -38.40 | -40.50 | -32.85 | -27.00 | -34.95 |
| Operating Cash Flow | -41.22 | -23.65 | -20.34 | -61.73 | -50.29 | -30.59 | -18.09 | -11.16 |
| Capital Expenditures | -0.40 | -0.04 | - | -2.59 | -5.23 | -2.80 | -0.72 | -0.85 |
| Free Cash Flow | -41.62 | -23.68 | -20.34 | -64.32 | -55.52 | -33.39 | -18.81 | -12.01 |
| Cash & Equivalents | 63.51 | 77.72 | 17.62 | 115 | 127 | 60.43 | 44.52 | 31.48 |
| Total Debt | 4.52 | 0.57 | 0.77 | - | - | - | - | - |
| Net Cash / Debt | 58.99 | 77.14 | 16.85 | 115 | 127 | 60.43 | 44.52 | 31.48 |
| Assets | 74.97 | 84.07 | 19.81 | 123 | 139 | 65.57 | 47.55 | 32.81 |
| Liabilities | 15.10 | 10.95 | 4.83 | 14.33 | 11.76 | 10.25 | 5.84 | 2.09 |
| Book Value | 58.55 | 70.95 | -131 | 108 | 127 | 55.33 | 41.70 | 30.72 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Millendo Therapeutics, Inc. |
| Country |
United States |
| Employees |
37 |
| CEO |
Julia C. Owens |
Stock Information
| Ticker Symbol |
MLND |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MLND |
Description
Millendo Therapeutics, a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia. Millendo Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.